promethazine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2286 60-87-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • promethazine
  • diphergan
  • proazamine
  • prometazin
  • protazine
  • promethazine hydrochloride
  • promethazine HCl
A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.
  • Molecular weight: 284.42
  • Formula: C17H20N2S
  • CLOGP: 4.60
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -4.07
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
25 mg O
25 mg P
25 mg R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 5.03 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 25 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 14 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 14 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.09 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 14 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
March 29, 1951 FDA DELCOR ASSET CORP

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intentional self-injury 6218.26 10.17 2042 75748 23242 53248034
Intentional overdose 5068.65 10.17 2294 75496 64911 53206365
Akathisia 499.88 10.17 246 77544 8325 53262951
Tachycardia 382.13 10.17 616 77174 107596 53163680
Depressed level of consciousness 369.99 10.17 426 77364 54002 53217274
Mydriasis 271.45 10.17 182 77608 11144 53260132
Drug ineffective 268.50 10.17 491 77299 816754 52454522
Cholecystitis chronic 264.11 10.17 174 77616 10344 53260932
Rheumatoid arthritis 238.11 10.17 81 77709 314450 52956826
Toxicity to various agents 187.92 10.17 724 77066 218874 53052402
Anxiety 171.10 10.17 652 77138 196052 53075224
Contraindicated product administered 161.19 10.17 9 77781 135620 53135656
Drug abuse 146.01 10.17 306 77484 65220 53206056
Synovitis 128.68 10.17 7 77783 107886 53163390
Nausea 128.07 10.17 1670 76120 754421 52516855
Suicide attempt 123.07 10.17 266 77524 57902 53213374
Hallucination 120.60 10.17 252 77538 53586 53217690
Treatment failure 120.46 10.17 21 77769 128382 53142894
Joint swelling 113.47 10.17 105 77685 234533 53036743
Drug intolerance 112.99 10.17 81 77709 205412 53065864
Off label use 110.13 10.17 339 77451 471873 52799403
Glossodynia 109.53 10.17 10 77780 100281 53170995
Vomiting 109.13 10.17 1155 76635 495984 52775292
Hand deformity 106.09 10.17 4 77786 84845 53186431
Poisoning 103.56 10.17 114 77676 13736 53257540
Completed suicide 103.14 10.17 437 77353 137764 53133512
Somnolence 99.68 10.17 496 77294 167238 53104038
Injury 92.12 10.17 219 77571 50752 53220524
Biliary dyskinesia 85.15 10.17 52 77738 2705 53268571
Gallbladder disorder 84.84 10.17 118 77672 18047 53253229
Agitation 83.26 10.17 230 77560 58396 53212880
Sinus tachycardia 80.05 10.17 132 77658 23440 53247836
Arthropathy 78.71 10.17 55 77735 141398 53129878
Systemic lupus erythematosus 76.31 10.17 44 77746 125370 53145906
Gallbladder injury 76.02 10.17 38 77752 1329 53269947
Emotional distress 75.56 10.17 154 77636 32163 53239113
Migraine 75.12 10.17 273 77517 80144 53191132
Therapeutic product effect decreased 72.40 10.17 47 77743 125608 53145668
Pericarditis 68.79 10.17 7 77783 64399 53206877
Infusion related reaction 66.09 10.17 78 77712 155879 53115397
Abdominal discomfort 63.32 10.17 143 77647 220919 53050357
Hepatic enzyme increased 61.50 10.17 56 77734 126139 53145137
Wound 58.78 10.17 30 77760 91527 53179749
Arthralgia 56.73 10.17 392 77398 439391 52831885
Accidental overdose 55.82 10.17 107 77683 21372 53249904
Rash 55.46 10.17 402 77388 445789 52825487
Serotonin syndrome 53.82 10.17 119 77671 26287 53244989
Snoring 52.80 10.17 44 77746 3748 53267528
Cholelithiasis 51.64 10.17 154 77636 40810 53230466
Alopecia 51.31 10.17 173 77617 234410 53036866
Muscle twitching 50.49 10.17 88 77702 16338 53254938
Product use issue 49.87 10.17 79 77711 139505 53131771
Therapeutic product effect incomplete 49.32 10.17 37 77753 91747 53179529
Respiratory arrest 49.01 10.17 133 77657 33407 53237869
Incoherent 48.68 10.17 46 77744 4626 53266650
Accidental death 46.27 10.17 30 77760 1734 53269542
Opisthotonus 46.20 10.17 18 77772 341 53270935
Dependence 45.60 10.17 32 77758 2109 53269167
Formication 44.61 10.17 41 77749 3980 53267296
Pulmonary haemorrhage neonatal 42.83 10.17 10 77780 25 53271251
Nasopharyngitis 42.59 10.17 141 77649 192154 53079122
Swelling 42.41 10.17 140 77650 190965 53080311
Mental status changes 40.95 10.17 139 77651 39432 53231844
Lethargy 40.82 10.17 171 77619 53589 53217687
Lower respiratory tract infection 40.15 10.17 44 77746 90937 53180339
Loss of consciousness 39.17 10.17 293 77497 113919 53157357
Hereditary angioedema 37.57 10.17 46 77744 6207 53265069
Pupillary reflex impaired 37.05 10.17 28 77762 2071 53269205
Suicidal ideation 36.62 10.17 180 77610 60331 53210945
Infection 36.28 10.17 129 77661 172076 53099200
Cardiac failure 36.27 10.17 43 77747 85801 53185475
Abdominal pain 35.95 10.17 548 77242 255355 53015921
Exposure via ingestion 35.74 10.17 33 77757 3222 53268054
Helicobacter infection 35.31 10.17 7 77783 39062 53232214
Dysarthria 33.95 10.17 133 77657 40435 53230841
Maternal exposure during pregnancy 33.85 10.17 115 77675 155524 53115752
Hypersensitivity 32.71 10.17 177 77613 210488 53060788
Deep vein thrombosis 32.67 10.17 220 77570 82693 53188583
Muscle injury 32.40 10.17 3 77787 29763 53241513
Drug hypersensitivity 32.39 10.17 555 77235 264687 53006589
Discomfort 32.26 10.17 56 77734 95416 53175860
Peripheral swelling 32.10 10.17 173 77617 205935 53065341
Impaired healing 31.85 10.17 28 77762 64177 53207099
Electrocardiogram QRS complex shortened 31.79 10.17 15 77775 461 53270815
Congenital tricuspid valve incompetence 31.76 10.17 10 77780 97 53271179
Depression 30.49 10.17 404 77386 182648 53088628
Folliculitis 30.13 10.17 5 77785 31704 53239572
C-reactive protein increased 29.77 10.17 33 77757 67853 53203423
Drug reaction with eosinophilia and systemic symptoms 29.38 10.17 6 77784 32794 53238482
General physical health deterioration 29.03 10.17 113 77677 146829 53124447
Newborn persistent pulmonary hypertension 28.51 10.17 10 77780 139 53271137
Neonatal hypotension 28.38 10.17 10 77780 141 53271135
Electrocardiogram QT prolonged 28.10 10.17 159 77631 56244 53215032
Anticholinergic syndrome 27.78 10.17 23 77767 1941 53269335
Drug screen positive 27.45 10.17 31 77759 3841 53267435
Drug abuser 27.19 10.17 28 77762 3125 53268151
Overdose 27.16 10.17 258 77532 107478 53163798
Dehydration 26.53 10.17 368 77422 168042 53103234
Cardiac arrest 25.99 10.17 229 77561 93438 53177838
Neonatal respiratory failure 24.81 10.17 10 77780 208 53271068
Restlessness 24.25 10.17 93 77697 27994 53243282
Product counterfeit 24.22 10.17 9 77781 149 53271127
Cholestasis 24.20 10.17 6 77784 28689 53242587
Impaired gastric emptying 23.43 10.17 45 77745 8998 53262278
Renal impairment 22.93 10.17 55 77735 83263 53188013
Somatic delusion 22.72 10.17 13 77777 599 53270677
Cardio-respiratory arrest 22.60 10.17 155 77635 58603 53212673
Mobility decreased 22.08 10.17 49 77741 76222 53195054
Neutropenia 21.90 10.17 139 77651 159046 53112230
Cholecystitis 21.81 10.17 60 77730 15186 53256090
Hyperreflexia 21.80 10.17 33 77757 5447 53265829
Gallbladder hypofunction 21.35 10.17 12 77778 534 53270742
Gastrointestinal disorder 21.31 10.17 64 77726 89940 53181336
Mental disorder 21.28 10.17 81 77709 24295 53246981
Hypopnoea 21.25 10.17 22 77768 2471 53268805
Arthritis 20.01 10.17 63 77727 87235 53184041
Gallbladder cholesterolosis 19.87 10.17 13 77777 763 53270513
Poor feeding infant 19.66 10.17 9 77781 258 53271018
Fatigue 18.99 10.17 1271 76519 729235 52542041
Drug withdrawal syndrome 18.87 10.17 86 77704 27936 53243340
Device expulsion 18.78 10.17 10 77780 29803 53241473
Cholecystectomy 18.62 10.17 43 77747 9772 53261504
Acute kidney injury 18.40 10.17 260 77530 253608 53017668
Pancreatitis chronic 18.16 10.17 20 77770 2410 53268866
Hip arthroplasty 18.07 10.17 9 77781 27853 53243423
Melaena 18.02 10.17 10 77780 29119 53242157
Cholesterosis 17.96 10.17 10 77780 437 53270839
Condition aggravated 17.94 10.17 315 77475 296819 52974457
Therapeutic response decreased 17.86 10.17 26 77764 47543 53223733
Pupil fixed 17.86 10.17 17 77773 1725 53269551
Seizure 17.63 10.17 276 77514 129233 53142043
Illness anxiety disorder 17.57 10.17 7 77783 141 53271135
Hepatocellular injury 17.55 10.17 11 77779 29975 53241301
Blood potassium decreased 17.54 10.17 110 77680 40350 53230926
Atrial septal defect 17.42 10.17 34 77756 6880 53264396
Coma blister 17.26 10.17 7 77783 148 53271128
Drug resistance 17.17 10.17 4 77786 19958 53251318
Helplessness 17.04 10.17 8 77782 243 53271033
Blood pressure fluctuation 16.96 10.17 16 77774 35454 53235822
Fall 16.87 10.17 396 77394 358044 52913232
Red blood cell sedimentation rate increased 16.83 10.17 10 77780 28047 53243229
Cytomegalovirus infection 16.64 10.17 4 77786 19535 53251741
Biliary colic 16.51 10.17 23 77767 3522 53267754
Miosis 15.93 10.17 33 77757 6969 53264307
Hyponatraemia 15.89 10.17 93 77697 108514 53162762
Musculoskeletal stiffness 15.82 10.17 110 77680 123258 53148018
Uterine perforation 15.76 10.17 34 77756 7385 53263891
Differential white blood cell count abnormal 15.62 10.17 11 77779 729 53270547
Blastocystis infection 15.52 10.17 4 77786 17 53271259
Product use in unapproved indication 15.46 10.17 98 77692 112191 53159085
Paranoia 15.40 10.17 44 77746 11380 53259896
Cough 15.29 10.17 273 77517 256620 53014656
Dyspnoea 14.90 10.17 701 77089 585531 52685745
Inflammation 14.72 10.17 39 77751 57097 53214179
Pneumocystis jirovecii pneumonia 14.66 10.17 3 77787 16375 53254901
Basal cell carcinoma 14.60 10.17 8 77782 23461 53247815
Pulmonary embolism 14.49 10.17 241 77549 114201 53157075
Ureteric stenosis 14.48 10.17 10 77780 642 53270634
Osteoporosis 14.15 10.17 29 77761 46431 53224845
Ill-defined disorder 14.11 10.17 32 77758 49412 53221864
pH body fluid increased 14.06 10.17 3 77787 4 53271272
Hypoglycaemia 13.94 10.17 42 77748 58971 53212305
Jaw clicking 13.85 10.17 4 77786 28 53271248
Sports injury 13.61 10.17 4 77786 30 53271246
Fear 13.47 10.17 54 77736 16587 53254689
Attention-seeking behaviour 13.39 10.17 5 77785 84 53271192
Herpes zoster 13.31 10.17 59 77731 73960 53197316
Intentional product misuse 13.30 10.17 120 77670 49272 53222004
Anhedonia 13.30 10.17 40 77750 10647 53260629
Fallot's tetralogy 13.02 10.17 5 77785 91 53271185
Ventricular septal defect 12.97 10.17 23 77767 4327 53266949
Loss of personal independence in daily activities 12.95 10.17 55 77735 69760 53201516
Interstitial lung disease 12.95 10.17 43 77747 58579 53212697
Unresponsive to stimuli 12.74 10.17 88 77702 33338 53237938
Heart rate increased 12.59 10.17 179 77611 82136 53189140
Base excess increased 12.51 10.17 4 77786 41 53271235
Vasoplegia syndrome 12.42 10.17 12 77778 1240 53270036
Osteonecrosis of jaw 12.39 10.17 21 77769 36125 53235151
Drug dependence 12.37 10.17 63 77727 21409 53249867
Stomatitis 12.34 10.17 88 77702 98070 53173206
Aggression 12.34 10.17 67 77723 23336 53247940
Hepatitis 12.27 10.17 19 77771 33875 53237401
Water intoxication 12.19 10.17 8 77782 472 53270804
Thrombocytopenia 11.92 10.17 137 77653 138590 53132686
Breast cancer 11.75 10.17 35 77755 49323 53221953
Chronic kidney disease 11.49 10.17 105 77685 43265 53228011
Pulmonary fibrosis 11.40 10.17 11 77779 24124 53247152
Fear of disease 11.39 10.17 11 77779 1136 53270140
Ischaemic stroke 11.39 10.17 6 77784 17987 53253289
Neuroleptic malignant syndrome 11.35 10.17 41 77749 11992 53259284
Infusion site macule 11.24 10.17 3 77787 15 53271261
Intestinal ischaemia 11.21 10.17 30 77760 7472 53263804
Finger amputation 11.20 10.17 8 77782 542 53270734
Small intestinal obstruction 11.09 10.17 52 77738 17095 53254181
Prolonged rupture of membranes 10.95 10.17 4 77786 63 53271213
Thinking abnormal 10.95 10.17 37 77753 10471 53260805
Jugular vein thrombosis 10.94 10.17 17 77773 2869 53268407
Acute lung injury 10.88 10.17 12 77778 1449 53269827
Injection site erythema 10.85 10.17 67 77723 77182 53194094
Hypophagia 10.81 10.17 80 77710 30982 53240294
Neonatal tachycardia 10.65 10.17 3 77787 19 53271257
Hyperkinetic heart syndrome 10.65 10.17 3 77787 19 53271257
Skin ulcer 10.62 10.17 23 77767 36096 53235180
Intestinal obstruction 10.57 10.17 75 77715 28666 53242610
Retroplacental haematoma 10.56 10.17 5 77785 155 53271121
Arm amputation 10.52 10.17 3 77787 20 53271256
Heart rate decreased 10.47 10.17 24 77766 36923 53234353
Lentigo 10.46 10.17 6 77784 278 53270998
Retching 10.32 10.17 44 77746 13889 53257387
Bradycardia 10.31 10.17 61 77729 70995 53200281
Tremor 10.28 10.17 248 77542 125488 53145788
Disorientation 10.28 10.17 95 77695 39264 53232012
Respiratory rate decreased 10.23 10.17 18 77772 3366 53267910
Femur fracture 10.21 10.17 27 77763 39558 53231718
Therapy non-responder 10.19 10.17 37 77753 49083 53222193
Knee arthroplasty 10.18 10.17 21 77769 33548 53237728

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intentional self-injury 1967.93 11.16 666 30101 13234 32469525
Intentional overdose 1549.74 11.16 764 30003 40837 32441922
Akathisia 146.07 11.16 88 30679 6937 32475822
Depressed level of consciousness 104.76 11.16 159 30608 40688 32442071
Neuroleptic malignant syndrome 87.64 11.16 95 30672 17400 32465359
Tachycardia 83.89 11.16 212 30555 78876 32403883
Agitation 68.75 11.16 161 30606 57075 32425684
Respiratory arrest 66.40 11.16 107 30660 28801 32453958
Nausea 64.18 11.16 520 30247 320329 32162430
Vomiting 63.96 11.16 411 30356 235146 32247613
Sinus tachycardia 63.47 11.16 78 30689 16336 32466423
Somnolence 61.66 11.16 227 30540 103570 32379189
Drug ineffective 60.10 11.16 176 30591 383301 32099458
Off label use 59.33 11.16 126 30641 306194 32176565
Mydriasis 59.23 11.16 49 30718 6397 32476362
Toxicity to various agents 54.14 11.16 320 30447 177721 32305038
Poisoning 49.70 11.16 57 30710 11101 32471658
Product counterfeit 41.99 11.16 13 30754 190 32482569
Drug abuse 40.69 11.16 167 30600 80076 32402683
Overdose 39.35 11.16 175 30592 86902 32395857
Lethargy 38.04 11.16 105 30662 41123 32441636
Exposure during pregnancy 37.53 11.16 45 30722 9184 32473575
Dysarthria 35.15 11.16 89 30678 33112 32449647
Hallucination 31.97 11.16 116 30651 52503 32430256
Dystonia 31.03 11.16 44 30723 10579 32472180
Loss of consciousness 30.66 11.16 157 30610 82550 32400209
Cardio-respiratory arrest 30.35 11.16 119 30648 55870 32426889
Consciousness fluctuating 29.04 11.16 16 30751 1064 32481695
Anxiety 26.23 11.16 168 30599 95837 32386922
Dehydration 25.61 11.16 209 30558 128749 32354010
Interstitial lung disease 25.38 11.16 15 30752 64986 32417773
Dextrocardia 25.23 11.16 8 30759 127 32482632
General physical health deterioration 25.19 11.16 44 30723 115215 32367544
Completed suicide 24.72 11.16 161 30606 92356 32390403
Serotonin syndrome 24.27 11.16 55 30712 19062 32463697
Pyomyositis 24.09 11.16 8 30759 148 32482611
Foetal alcohol syndrome 24.09 11.16 8 30759 148 32482611
Acute kidney injury 23.49 11.16 172 30595 293296 32189463
Renal impairment 22.08 11.16 33 30734 91939 32390820
Atrial septal defect 21.87 11.16 30 30737 6995 32475764
Failure to thrive 21.83 11.16 33 30734 8402 32474357
Exposure via ingestion 21.82 11.16 18 30749 2339 32480420
Opisthotonus 21.72 11.16 10 30757 453 32482306
Suicide attempt 21.30 11.16 82 30685 38162 32444597
Sedation 21.01 11.16 51 30716 18475 32464284
General symptom 20.70 11.16 12 30755 880 32481879
Paralysis 20.22 11.16 27 30740 6136 32476623
Foetal exposure during pregnancy 20.16 11.16 85 30682 41216 32441543
Hepatic ischaemia 19.73 11.16 9 30758 399 32482360
Breathing-related sleep disorder 18.92 11.16 7 30760 180 32482579
Confusional state 18.53 11.16 212 30555 142903 32339856
Drug withdrawal syndrome neonatal 17.22 11.16 19 30748 3545 32479214
Therapeutic product effect incomplete 16.91 11.16 9 30758 41332 32441427
Pupil fixed 16.85 11.16 14 30753 1837 32480922
Respiratory depression 16.76 11.16 38 30729 13173 32469586
Rheumatoid arthritis 16.39 11.16 11 30756 44533 32438226
Angioedema 16.22 11.16 7 30760 36282 32446477
Drug withdrawal syndrome 16.21 11.16 49 30718 20182 32462577
Psychomotor hyperactivity 16.21 11.16 30 30737 9009 32473750
Conduction disorder 15.97 11.16 14 30753 1976 32480783
Obsessive thoughts 15.25 11.16 9 30758 682 32482077
Red blood cells urine positive 15.22 11.16 13 30754 1773 32480986
Cardiac arrest 15.16 11.16 149 30618 96627 32386132
Patent ductus arteriosus 15.00 11.16 17 30750 3268 32479491
Fallot's tetralogy 14.90 11.16 6 30761 195 32482564
Inappropriate schedule of product administration 14.72 11.16 13 30754 45812 32436947
Condition aggravated 14.55 11.16 87 30680 155574 32327185
Unresponsive to stimuli 14.40 11.16 58 30709 27551 32455208
Skin swelling 14.14 11.16 10 30757 1034 32481725
Snoring 14.11 11.16 16 30751 3077 32479682
Drug hypersensitivity 14.03 11.16 118 30649 73282 32409477
Fatigue 13.95 11.16 432 30335 350269 32132490
Upper respiratory tract irritation 13.88 11.16 4 30763 45 32482714
Incision site pain 13.74 11.16 13 30754 2024 32480735
Psoriasis 13.74 11.16 14 30753 46109 32436650
Linear IgA disease 13.68 11.16 12 30755 1696 32481063
Product use in unapproved indication 13.58 11.16 40 30727 87164 32395595
Cardiomegaly 13.51 11.16 38 30729 15033 32467726
Environmental exposure 13.35 11.16 6 30761 257 32482502
Protein urine present 13.27 11.16 20 30747 5077 32477682
Poor quality product administered 13.24 11.16 12 30755 1769 32480990
Foetal death 13.24 11.16 6 30761 262 32482497
Hyperkalaemia 13.18 11.16 29 30738 69721 32413038
Myocardial infarction 12.96 11.16 68 30699 125608 32357151
Accidental overdose 12.91 11.16 44 30723 19295 32463464
Hepatocellular injury 12.80 11.16 4 30763 25314 32457445
Drug resistance 12.80 11.16 3 30764 22962 32459797
Restlessness 12.76 11.16 52 30715 24829 32457930
Treatment failure 12.71 11.16 11 30756 39152 32443607
Psychotic disorder 12.52 11.16 49 30718 22971 32459788
Cholestasis 12.43 11.16 5 30762 27028 32455731
Acute chest syndrome 12.28 11.16 6 30761 311 32482448
Drug interaction 12.15 11.16 140 30627 218045 32264714
Tardive dyskinesia 12.05 11.16 20 30747 5511 32477248
Aggression 12.05 11.16 71 30696 39318 32443441
Small for dates baby 11.34 11.16 15 30752 3378 32479381

Pharmacologic Action:

SourceCodeDescription
ATC D04AA10 DERMATOLOGICALS
ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
Antihistamines for topical use
ATC R06AD02 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Phenothiazine derivatives
ATC R06AD52 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Phenothiazine derivatives
ATC V03AB05 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Antidotes
FDA CS M0016525 Phenothiazines
MeSH PA D018926 Anti-Allergic Agents
MeSH PA D000982 Antipruritics
MeSH PA D003879 Dermatologic Agents
MeSH PA D018494 Histamine Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D018377 Neurotransmitter Agents
CHEBI has role CHEBI:35717 sedatives
CHEBI has role CHEBI:36333 local anaesthetics
CHEBI has role CHEBI:37955 H1-receptor blockers
CHEBI has role CHEBI:50857 anti-allergic agents
CHEBI has role CHEBI:50919 antiemetico
CHEBI has role CHEBI:59683 anti-itching drug
CHEBI has role CHEBI:149553 anti-coronaviral agents
CHEBI has role CHEBI:176497 anti-aging drugs
FDA EPC N0000175746 Phenothiazine

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Vasomotor rhinitis indication 8229003 DOID:4730
Nausea and vomiting indication 16932000
General anesthesia indication 50697003
Sedation indication 72641008
Urticaria indication 126485001
Seasonal allergic rhinitis indication 367498001
Allergic conjunctivitis indication 473460002 DOID:11204

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.19 Basic
pKa2 3.55 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST Ki 9.62 WOMBAT-PK CHEMBL
D(2) dopamine receptor GPCR Ki 6.61 WOMBAT-PK
Alpha-2A adrenergic receptor GPCR Ki 6.59 DRUG MATRIX
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 6.92 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter IC50 5.12 CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 5.38 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 5.83 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 6.77 WOMBAT-PK
5-hydroxytryptamine receptor 2B GPCR Ki 7.37 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 8.19 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 5.95 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 7.62 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.72 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.94 DRUG MATRIX
Histamine H4 receptor GPCR Ki 6.82 WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR Ki 8.48 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 7.92 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 8.38 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 8.98 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 8.48 DRUG MATRIX
Aldehyde oxidase Enzyme IC50 6.29 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 6.45 DRUG MATRIX
Cytochrome P450 2D6 Enzyme Ki 5.42 WOMBAT-PK
Alpha-1D adrenergic receptor GPCR Ki 7.50 DRUG MATRIX
Cholinesterase Enzyme Ki 7.10 WOMBAT-PK
Major prion protein Surface antigen EC50 5.10 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.45 CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 5.16 CHEMBL
FAD-linked sulfhydryl oxidase ALR Enzyme AC50 6.44 CHEMBL
D(1A) dopamine receptor GPCR Ki 5.86 DRUG MATRIX
Calmodulin-1 Cytosolic other IC50 4.22 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 7.68 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 7.10 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 5.59 CHEMBL
Pleiotropic ABC efflux transporter of multiple drugs Transporter IC50 4.75 CHEMBL
Chloroquine resistance transporter Transporter IC50 4.07 CHEMBL
Calmodulin Cytosolic other Kd 4.30 CHEMBL

External reference:

IDSource
4019910 VUID
N0000147995 NUI
D00480 KEGG_DRUG
58-33-3 SECONDARY_CAS_RN
4017846 VANDF
4019910 VANDF
C0033405 UMLSCUI
CHEBI:8461 CHEBI
CHEMBL1200750 ChEMBL_ID
CHEMBL251904 ChEMBL_ID
CHEMBL643 ChEMBL_ID
DB01069 DRUGBANK_ID
D011398 MESH_DESCRIPTOR_UI
4927 PUBCHEM_CID
7282 IUPHAR_LIGAND_ID
516 INN_ID
FF28EJQ494 UNII
142445 RXNORM
2141 MMSL
5367 MMSL
d00787 MMSL
001483 NDDF
004459 NDDF
14905007 SNOMEDCT_US
372871004 SNOMEDCT_US
8372007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE HUMAN PRESCRIPTION DRUG LABEL 2 0121-0547 SYRUP 6.25 mg ORAL ANDA 30 sections
Promethazine VC with Codeine Oral Solution HUMAN PRESCRIPTION DRUG LABEL 3 0121-0925 SOLUTION 6.25 mg ORAL ANDA 29 sections
Promethazine VC HUMAN PRESCRIPTION DRUG LABEL 2 0121-0926 SOLUTION 6.25 mg ORAL ANDA 25 sections
Promethazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0121-0927 SOLUTION 6.25 mg ORAL ANDA 25 sections
Promethazine with Codeine HUMAN PRESCRIPTION DRUG LABEL 2 0121-0928 SOLUTION 6.25 mg ORAL ANDA 29 sections
PROMETHAZINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9940 INJECTION 25 mg INTRAMUSCULAR ANDA 12 sections
Promethazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9941 INJECTION 25 mg INTRAMUSCULAR ANDA 12 sections
Promethazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9942 INJECTION 50 mg INTRAMUSCULAR ANDA 12 sections
Promethazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0440-5195 TABLET 25 mg ORAL ANDA 11 sections
Promethazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0440-8195 TABLET 25 mg ORAL ANDA 12 sections
Promethazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-5307 TABLET 25 mg ORAL ANDA 24 sections
Promethazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-5319 TABLET 50 mg ORAL ANDA 24 sections
Promethazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8154 TABLET 25 mg ORAL ANDA 21 sections
Promethazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-0928 INJECTION 25 mg INTRAMUSCULAR ANDA 25 sections
Promethazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-0929 INJECTION 50 mg INTRAMUSCULAR ANDA 25 sections
Promethazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-0948 INJECTION 25 mg INTRAMUSCULAR ANDA 25 sections
Promethazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-0949 INJECTION 50 mg INTRAMUSCULAR ANDA 25 sections
Promethazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-0955 INJECTION 25 mg INTRAMUSCULAR ANDA 25 sections
Promethazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-0956 INJECTION 50 mg INTRAMUSCULAR ANDA 25 sections
Promethazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-1495 INJECTION 25 mg INTRAMUSCULAR ANDA 25 sections
Promethazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-1496 INJECTION 50 mg INTRAMUSCULAR ANDA 25 sections
PHENERGAN HUMAN PRESCRIPTION DRUG LABEL 1 0641-6082 INJECTION 25 mg INTRAMUSCULAR ANDA 25 sections
PHENERGAN HUMAN PRESCRIPTION DRUG LABEL 1 0641-6083 INJECTION 50 mg INTRAMUSCULAR ANDA 25 sections
PHENERGAN HUMAN PRESCRIPTION DRUG LABEL 1 0641-6084 INJECTION 25 mg INTRAMUSCULAR ANDA 26 sections
PHENERGAN HUMAN PRESCRIPTION DRUG LABEL 1 0641-6085 INJECTION 50 mg INTRAMUSCULAR ANDA 26 sections
Promethazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-6099 INJECTION 25 mg INTRAMUSCULAR ANDA 26 sections
Promethazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-6208 INJECTION 25 mg INTRAMUSCULAR ANDA 25 sections
PROMETHEGAN HUMAN PRESCRIPTION DRUG LABEL 1 0713-0132 SUPPOSITORY 50 mg RECTAL ANDA 21 sections
PROMETHEGAN HUMAN PRESCRIPTION DRUG LABEL 1 0713-0526 SUPPOSITORY 25 mg RECTAL ANDA 21 sections
PROMETHEGAN HUMAN PRESCRIPTION DRUG LABEL 1 0713-0536 SUPPOSITORY 12.50 mg RECTAL ANDA 21 sections